Table 4 Real-life cohort studies that evaluated efficacy (SVR12) of Sofosbuvir/Daclastavir (SOF/DCV) or Sofosbuvir/Simeprevir (SOF/SIM) regimens for treatment of HCV mono-infected genotype-1 patients
Authors | Year | Local | Regimen | Overall | Non-cirrhosis | Cirrhosis | Naive | Experimented | GT 1a | GT 1b | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | n | SVR | n | SVR | n | SVR | n | SVR | n | SVR | n | SVR | n | SVR |
Sofosbuvir (400Â mg)/Daclastavir (60Â mg) regimen studies | |||||||||||||||||
 Pol et al. [17] | 2017 | France | SOF/DCV 12w | 160 | 92% | 66 | 98% | 94 | 87% | 64 | 88% | 96 | 95% | 73 | 95% | 83 | 89% |
| Â | Â | Â | SOF/DCV 24w | 439 | 95% | 97 | 97% | 342 | 94% | 48 | 85% | 391 | 96% | 210 | 95% | 209 | 95% |
 Welzel et al. [16] | 2016 | Europe | SOF/DCV ± RBV 12w | 319 | 98% | – | – | – | – | – | – | – | – | 151 | 99% | 155 | 97% |
Sofosbuvir (400Â mg)/Simeprevir (150Â mg) regimen studies | |||||||||||||||||
 Marino et al. [[28] | 2017 | Spain | SOF/SIM ± RBV 12w | 835 | 92% | – | – | 835 | 92% | – | – | – | – | – | – | – | – |
 Ramos et al. [29] | 2017 | Spain | SOF/SIM 12w | 179 | 93% | – | – | – | – | – | – | – | – | – | – | – | – |
 Chang et al. [27] | 2017 | USA | SOF/SIM 12w | 21 | 91% | – | – | – | – | – | – | – | – | – | – | – | – |
 Sulkowski et al. [26] | 2016 | USA | SOF/SIM 12w | 639 | 85% | 272 | 91% | 367 | 81% | 65 | – | – | – | 371 | 83% | 185 | 90% |
 Lutchtman et al. [25] | 2016 | USA | SOF/SIM 12w | 148 | 82% | 43 | 88% | 193 | 78% | 62 | 87% | 86 | 78% | 94 | 79% | 42 | 93% |
 Pellicelli et al. [24] | 2016 | Italy | SOF/SIM/RBV 12w | 270 | 96% | – | – | 270 | 96% | – | – | – | – | – | – | – | – |
 Roytman et al. [23] | 2016 | USA | SOF/SIM 12w | 138 | 89% | 43 | 93% | 95 | 87% | 76 | 87% | 55 | 92% | – | – | – | – |
 Thornton et al. [22] | 2016 | USA | SOF/SIM 12w | 114 | 89% | – | – | – | – | – | – | – | – | – | – | – | – |
 Jayasekera et al. [19] | 2016 | USA | SOF/SIM 12w | 35 | 86% | 13 | 92% | 22 | 82% | 7 | 86% | 28 | 86% | – | – | – | – |
 Pillail et al. [20] | 2016 | USA | SOF/SIM ± RBV 12w | 113 | 84% | 23 | 91% | 90 | 82% | 57 | 89% | 56 | 79% | – | – | – | – |
 Barron et al. [21] | 2016 | USA | SOF/SIM ± RBV 12w | 35 | 83% | – | – | – | – | – | – | – | – | – | – | – | – |
 Backus et al. [18] | 2015 | USA | SOF/SIM 12w | 1130 | 75% | 664 | 81% | 462 | 68% | 699 | 78% | 431 | 71% | 632 | 73% | 366 | 80% |